Laurus Labs: Company Confident It Will Achieve At Least 50% of Total Revenue from CDMO Segment by FY '30. Company's Initial Target for Asset Turnover Ratio Is Above 1.0, While ROCE Currently at 19% Aims for 23% but Will Take Time Due to Significant Capital Expenditures This Year.

 25 Jul 2026 12:10 PM

Laurus Labs: Company Confident It Will Achieve At Least 50% of Total Revenue from CDMO Segment by FY '30. Company's Initial Target for Asset Turnover Ratio Is Above 1.0, While ROCE Currently at 19% Aims for 23% but Will Take Time Due to Significant Capital Expenditures This Year.

Laurus Labs: Co. On Track To Boost Capital Expenditure For Growth In Human And Animal Health, Peptides, Gene Therapy, And Antibody Drug Conjugates For FY27 And FY28.

 24 Jul 2026 03:00 PM

Laurus Labs: Co. On Track To Boost Capital Expenditure For Growth In Human And Animal Health, Peptides, Gene Therapy, And Antibody Drug Conjugates For FY27 And FY28.

LAURUS LABS: Q1 CONS NET PROFIT 3.7B RUPEES VS 1.63B (YOY); EST 2.7B

 24 Jul 2026 02:48 PM

LAURUS LABS: Q1 CONS NET PROFIT 3.7B RUPEES VS 1.63B (YOY); EST 2.7B

LAURUS LABS: Q1 EBITDA 6.44B RUPEES VS 3.82B (YOY) || Q1 EBITDA MARGIN 31.8% VS 24.35% (YOY)

 24 Jul 2026 02:48 PM

LAURUS LABS: Q1 EBITDA 6.44B RUPEES VS 3.82B (YOY) || Q1 EBITDA MARGIN 31.8% VS 24.35% (YOY)

LAURUS LABS: Q1 REVENUE 20.3B RUPEES VS 15.7B (YOY)

 24 Jul 2026 02:49 PM

LAURUS LABS: Q1 REVENUE 20.3B RUPEES VS 15.7B (YOY)

Laurus Labs: Company Plans Q1 Earnings Call On July 24 At 5 PM

 09 Jul 2026 07:21 PM

Laurus Labs: Company Plans Q1 Earnings Call On July 24 At 5 PM